IRCT20200329046892N1 IRCT 2020-05-02 Rasht University of Medical Sciences Trifluoperazine Effectiveness in Treatment of Coronavirus Evaluation of Trifluoperazine Effectiveness in Treatment Process, Survival rate and Cure rate of COVID-19 Patients 2020-05-04 anticipated 70 Complete https://irct.ir/trial/47300 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 70 COVID-19 patients divide to 2 groups each comprising 35 patients, case and control naming A and B, respectively. Randomized blocking will conduct as numbers 1-70 allocate consequently to research units. Then a table will draw including 6 rows named Block, each block having 4 segments filled with A and B. In next stage, the numbers will placed next to each other. The subjects would received A package if they had the numbers placed in A segment. About the subjects being opposite to B segments, B package would allocate to them. Concealment is done via sealed package, Blinding description: Treatment group would be determined just after randomization. Subjects and physicians corresponding to patients' health would n't be blinded. Radiologists, main researchers, outcome assessor and statistician would be blinded to treatment group. 2-3 COVID-19. Intervention 1: Intervention group: Recommended standard care for COVID-19 patients + Trifluoperazine, 2 mg tablet PO (manufactured by Sobhandarou, Iran) q12hr for 21 days. Intervention 2: Control group: Recommended standard care for COVID-19 patients. Yes - There is a plan to make this available What will be shared: Data about outcomes When: Summer 2020 To whom: researchers Conditions: requested by authenticated scientific centers and universities Where to obtain: Dr. Nematollah Ahangar School of Medicine How to obtain: Official request signed by highest executive is mandatory. Moreover, acceptable reasons should be noted. Comments: